Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $325.3 million.

  • Axsome Therapeutics' Cash & Equivalents fell 0.62% to $325.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $325.3 million, marking a year-over-year decrease of 0.62%. This contributed to the annual value of $315.4 million for FY2024, which is 18.34% down from last year.
  • Axsome Therapeutics' Cash & Equivalents amounted to $325.3 million in Q3 2025, which was up 7.35% from $303.0 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Cash & Equivalents ranged from a high of $437.1 million in Q2 2023 and a low of $73.4 million during Q2 2022.
  • Over the past 3 years, Axsome Therapeutics' median Cash & Equivalents value was $325.3 million (recorded in 2025), while the average stood at $336.9 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Cash & Equivalents surged by 495.52% in 2023, and later decreased by 27.78% in 2024.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Cash & Equivalents stood at $200.8 million in 2022, then surged by 92.29% to $386.2 million in 2023, then dropped by 18.34% to $315.4 million in 2024, then declined by 0.62% to $325.3 million in 2025.
  • Its last three reported values are $325.3 million in Q3 2025, $303.0 million for Q2 2025, and $300.9 million during Q1 2025.